Skip to content

Study on the efficacy and safety of different insuline models in the treatment of uncontrolled type 2 diabetes patients

Study on the efficacy and safety of different insuline models in the treatment of uncontrolled type 2 diabetes patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17011177
Enrollment
Unknown
Registered
2017-04-18
Start date
2014-06-01
Completion date
Unknown
Last updated
2017-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

case series:1 + 1 breakfast premixing model

Sponsors

The Affiliated Hospital of Ningbo University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 82 Years

Inclusion criteria

Inclusion criteria: Subjects were patients with type 2 diabetes mellitus (World Health Organization, 1999), aged 50-82 years, with a disease duration of 10-30 years, stable use of insulin glargine + 1 Insulin aspartate before primary dining model (1 + 1 mode) for at least 3 months; HbA1C> 7.5% but 11.0mmol/l for at least one meal. Willing and able to use blood glucose meter for blood glucose monitoring, willing and able to fill out the research questionnaire, willing and able to sign the written informed consent before enrollment.

Exclusion criteria

Exclusion criteria: (1) non-type 2 diabetes (such as type 1 diabetes, diabetes secondary to pancreatic disease, taking drugs or chemicals); (2) pregnant women, pregnant or lactating women; (3) accompanied by acute complications of diabetes such as diabetic ketoacidosis, hypertonic faint patients; (4) liver and kidney dysfunction patients (alanine aminotransferaseexceeds limit of more than 2 times; significant kidney disease or serum creatinine =133umol/L); (5) diabetic patients associated with other endocrine and metabolic diseases, newly discovered tumors, autoimmune diseases; (6) diabetic patients with thyroid, pituitary, adrenal and other diseases; (7) Participated in other researchers at the same time orwithin 3 months; (8) using steroid hormone therapy and so on within recent 3 months.

Design outcomes

Primary

MeasureTime frame
Fasting blood glucose;2hPG;HbA1C;BMI;Daily insulin dose;Hypoglycemic events;DTSQs/c;

Countries

China

Contacts

Public ContactLi Jing

The Affiliated Hospital of Ningbo University School of Medicine

627168316@QQ.com+86 13586626178

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026